Literature DB >> 24903768

Soft tissue sarcoma: an update on systemic treatment options for patients with advanced disease.

Patrick Schöffski1, Jasmien Cornillie, Agnieszka Wozniak, Haifu Li, Daphne Hompes.   

Abstract

Sarcomas are a group of rare solid tumours arising from mesenchymal or connective tissue. This review focuses on soft tissue sarcoma and covers general topics such as the epidemiology, age distribution, site of disease, histogenesis, histological subtypes, prognosis and outcome of treatment. In more detail, the article reviews current systemic treatment standards and selected adverse events of agents such as doxorubicin, ifosfamide, trabectedin and pazopanib, and briefly highlights some drugs that are used off-label in specific subtypes of sarcoma.
© 2014 S. Karger GmbH, Freiburg.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24903768     DOI： 10.1159/000362631

Source DB:  PubMed          Journal:  Oncol Res Treat        ISSN： 2296-5270            Impact factor:   2.825


  43 in total

1.  Feasibility and clinical value of CT-guided 125I brachytherapy for metastatic soft tissue sarcoma after first-line chemotherapy failure.

Authors:  Zhiqiang Mo; Tao Zhang; Yanling Zhang; Zhanwang Xiang; Huzhen Yan; Zhihui Zhong; Fei Gao; Fujun Zhang
Journal:  Eur Radiol       Date:  2017-09-27       Impact factor: 5.315

2.  Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification.

Authors:  J Cornillie; A Wozniak; H Li; Y K Gebreyohannes; J Wellens; D Hompes; M Debiec-Rychter; R Sciot; P Schöffski
Journal:  Clin Transl Oncol       Date:  2019-06-14       Impact factor: 3.405

3.  Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.

Authors:  George D Demetri; Margaret von Mehren; Robin L Jones; Martee L Hensley; Scott M Schuetze; Arthur Staddon; Mohammed Milhem; Anthony Elias; Kristen Ganjoo; Hussein Tawbi; Brian A Van Tine; Alexander Spira; Andrew Dean; Nushmia Z Khokhar; Youn Choi Park; Roland E Knoblauch; Trilok V Parekh; Robert G Maki; Shreyaskumar R Patel
Journal:  J Clin Oncol       Date:  2015-09-14       Impact factor: 44.544

4.  Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.

Authors:  Martee L Hensley; Shreyaskumar R Patel; Margaret von Mehren; Kristen Ganjoo; Robin L Jones; Arthur Staddon; Daniel Rushing; Mohammed Milhem; Bradley Monk; George Wang; Sharon McCarthy; Roland E Knoblauch; Trilok V Parekh; Robert G Maki; George D Demetri
Journal:  Gynecol Oncol       Date:  2017-06-24       Impact factor: 5.482

5.  Development of a Novel Humanized Monoclonal Antibody to Secreted Frizzled-Related Protein-2 That Inhibits Triple-Negative Breast Cancer and Angiosarcoma Growth In Vivo.

Authors:  Denise Garcia; Patrick Nasarre; Ingrid V Bonilla; Eleanor Hilliard; Yuri K Peterson; Laura Spruill; Anne-Marie Broome; Elizabeth G Hill; Jason T Yustein; Shikhar Mehrotra; Nancy Klauber-DeMore
Journal:  Ann Surg Oncol       Date:  2019-09-12       Impact factor: 5.344

6.  Xenograft models for undifferentiated pleomorphic sarcoma not otherwise specified are essential for preclinical testing of therapeutic agents.

Authors:  Marc Becker; Claudine Graf; Marcus Tonak; Markus P Radsak; Tobias Bopp; Robert Bals; Rainer M Bohle; Matthias Theobald; Pol-Maria Rommens; Dirk Proschek; Thomas C Wehler
Journal:  Oncol Lett       Date:  2016-06-24       Impact factor: 2.967

7.  Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.

Authors:  Mrinal M Gounder; Alona Zer; William D Tap; Samer Salah; Mark A Dickson; Abha A Gupta; Mary Louise Keohan; Herbert H Loong; Sandra P D'Angelo; Stephanie Baker; Mercedes Condy; Kjirsten Nyquist-Schultz; Lanier Tanner; Joseph P Erinjeri; Francis H Jasmine; Sharon Friedlander; Robert Carlson; Thaddeus J Unger; Jean-Richard Saint-Martin; Tami Rashal; Joel Ellis; Michael Kauffman; Sharon Shacham; Gary K Schwartz; Albiruni Ryan Abdul Razak
Journal:  J Clin Oncol       Date:  2016-07-25       Impact factor: 44.544

Review 8.  Systemic therapy for selected skull base sarcomas: Chondrosarcoma, chordoma, giant cell tumour and solitary fibrous tumour/hemangiopericytoma.

Authors:  Vittoria Colia; Salvatore Provenzano; Nadia Hindi; Paolo G Casali; Silvia Stacchiotti
Journal:  Rep Pract Oncol Radiother       Date:  2016-01-13

Review 9.  [Retroperitoneal tumors].

Authors:  O Schmalz
Journal:  Urologe A       Date:  2016-06       Impact factor: 0.639

10.  Long-Term Response after 94 Cycles of Trabectedin in a Patient with Metastatic Leiomyosarcoma of the Lower Extremity.

Authors:  Magda Cordeiro; José Manuel Casanova; Joana Rodrigues; João Freitas; Ruben Fonseca; Rui Caetano de Oliveira; Paulo Freitas Tavares
Journal:  Case Rep Oncol       Date:  2020-02-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.